The problem nobody mentions in the ads
GLP-1 and GIP/GLP-1 agonists — semaglutide, tirzepatide, retatrutide — work by suppressing appetite, which produces fast, large weight loss. The catch is what you lose. In the controlled trials, a substantial fraction of the weight lost was lean mass, not fat:
- On semaglutide (the STEP-1 DXA data), roughly 40% of the weight lost was lean/fat-free mass.
- On tirzepatide (SURMOUNT-1 body-composition data), the lean fraction was more favorable, around 25–34% of weight lost.
These figures are without a deliberate muscle-preservation strategy. Rapid weight loss on a heavily suppressed appetite is a recipe for catabolism: intake crashes, protein often falls below target, and the body breaks down muscle alongside fat. The entire job of nutrition on a GLP-1 is to push that lean fraction down — toward fat-only loss — by giving the body a reason to keep its muscle.
Protein is the lever; resistance training is the signal
Two interventions move the lean-loss number, and both are non-negotiable. Protein, hit first on every plate (the 1.6–2.2 g/kg bodyweight range from the last chapter, leaning higher as you lean out), supplies the raw material. Resistance training supplies the signal that tells the body the muscle is still needed. Protein without training, or training without protein, each leaves muscle on the table; together they are what separates a GLP-1 cut that reveals a lean physique from one that produces a smaller, softer version of the same person.
The anti-pattern: do not stack a deficit on a deficit
The most important rule on a GLP-1 is what not to do. The drug is already creating your deficit. Layering a large voluntary calorie restriction on top of pharmacologic appetite suppression deepens the deficit, accelerates muscle loss, and — because the drug already blunts hunger — frequently drops you below the protein intake you need to defend that muscle. Let the drug set the deficit. Your job is not to eat less; it is to eat enough protein and train, within the smaller appetite the drug gives you. Chasing a faster scale number by also slashing calories is how people end up skinny-fat on a medication that should have left them lean.
Eating against a suppressed appetite
When solid food won't go down, structure beats willpower. Small, calorie-dense, high-protein meals; a protein-first plate every time; and liquid protein (whey isolate shakes) on days the appetite is lowest. Fat is worth moderating in the post-dose window — very high-fat meals further slow gastric emptying and worsen nausea. Fiber and hydration manage the constipation that commonly comes with reduced intake, but ramp fiber up slowly. Because weekly-dose drugs peak a day or two after injection, intake is often easiest later in the cycle and toughest right after the dose — front-load nutrition into the better-appetite days rather than forcing it by the clock.
The micronutrient blind spot, and the exit
When total food intake drops hard, micronutrient and electrolyte intake quietly drops with it — a real risk on aggressive GLP-1 loss that a multivitamin and attention to electrolytes help cover. And the hardest part is the exit. Coming off the drug, appetite returns; if you snap back to old intake on a metabolism that has adapted down, you regain — often with a worse body composition than you started, because you lost muscle and regain fat. The exit is a reverse diet: taper the drug slowly, raise calories gradually as appetite returns, keep protein and resistance training non-negotiable through and past the taper, and hold the new weight long enough for it to stick.
Educational content, not individual medical advice.